SW-1736 Cells

SW-1736 is a human thyroid anaplastic carcinoma cell line, commonly used to study aggressive and poorly differentiated thyroid cancers. This cell line was initially derived from a patient with undifferentiated thyroid carcinoma, a rare but highly aggressive form of cancer characterized by its rapid progression and poor prognosis. The SW-1736 cell line has been employed extensively in cancer research due to its ability to replicate the highly malignant features of anaplastic thyroid cancer (ATC), including resistance to standard therapies such as chemotherapy and radiation. One prominent feature of the SW-1736 cell line is its frequent use in studies focusing on cell division abnormalities and tumor metastasis. Researchers have observed atypical cell division events, such as one-to-four cell divisions, which are indicative of the aggressive and uncontrollable growth patterns found in anaplastic thyroid carcinomas. Additionally, SW-1736 cells have been transfected with various reporter genes like luciferase, allowing for non-invasive in vivo imaging studies. These studies are often performed in mouse models to investigate the metastatic potential of thyroid cancer, particularly its spread to organs such as the lungs and bones. Moreover, SW-1736 has been used to explore potential treatment strategies, including the combined use of metformin with standard chemotherapy agents like etoposide and epirubicin. These studies suggest that metformin enhances the cytotoxic effects of these drugs, increasing the induction of apoptosis and necrosis in SW-1736 cells. This combination therapy has shown promise in reducing cancer cell migration and proliferation, potentially offering new therapeutic avenues for tackling aggressive thyroid cancers.